

## NCCN Breast Cancer Interim Update .2.2011 – 11/29/10

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
BINV-17 Internal request: Should denosumab be added as a treatment option for patients with bone metastases?	Based on the FDA prescribing information and referenced data, the panel consensus was to add denosumab as a treatment option for patients with bone metastases.	<ul style="list-style-type: none"> <li>Prescribing information for denosumab: <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125320s0071bl.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125320s0071bl.pdf</a></li> <li>Stopeck AT, Lipton A, Body JJ, et al. Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study. J Clin Oncol 2010;28:epub ahead of print. Available at: <a href="http://www.ncbi.nlm.nih.gov/pubmed/21060033">http://www.ncbi.nlm.nih.gov/pubmed/21060033</a></li> </ul>	16	0	0
BINV-N Internal request and external submission: Review of data for eribulin mesylate for the treatment of metastatic breast cancer.	Based on the referenced data the panel consensus was to include eribulin to the list of preferred single agents for recurrent or metastatic breast cancer.	<ul style="list-style-type: none"> <li>Twelves C, Loesch D, Blum JL, et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane [abstract]. J Clin Oncol 2010;28(Suppl 18):Abstract CRA1004. Available at: <a href="http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/CRA1004">http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/CRA1004</a></li> </ul>	16	0	0